Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline trading services limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - lamivudine - hepatitis b, chronic - antivirals for systemic use - zeffix is indicated for the treatment of chronic hepatitis b in adults with: , compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate;, decompensated liver disease in combination with a second agent without cross-resistance to lamivudine.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus inactivated, containing antigen equivalent to a/california/07/2009 (h1n1)-derived strain used nymc x-179a - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1)v 2009 virus. pandemrix should only be used if the recommended annual seasonal trivalent / quadrivalent influenza vaccines are not available and if immunisation against (h1n1)v is considered necessary (see sections 4.4 and 4.8).pandemrix should be used in accordance with official guidance.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with h5n1 subtype strains.prepandrix should be used in accordance with official guidance.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted)  - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic-influenza vaccine should be used in accordance with official guidance.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemic - immunosuppressants - benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g., positive anti dsdna and low complement) despite standard therapy.benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, hepatitis b surface antigen, bordetella pertussis (inactivated), tetanus toxoid - hepatitis b; tetanus; immunization; whooping cough; diphtheria - vaccines - tritanrix hepb is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis b (hbv) in infants from six weeks onwards (see section 4.2).

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - sumatriptan succinate - oral tablet - 50mg

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline trading services limited - zanamivir - influenza, human - antivirals for systemic use - dectova is indicated for the treatment of complicated and potentially life-threatening influenza a or b virus infection in adult and paediatric patients (aged ≥6 months) when:the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orother anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.dectova should be used in accordance with official guidance.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratory syncytial virus infections - vaccines - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older.the use of this vaccine should be in accordance with official recommendations.